1.31
-0.12(-8.39%)
Currency In USD
| Previous Close | 1.43 |
| Open | 1.44 |
| Day High | 1.44 |
| Day Low | 1.31 |
| 52-Week High | 3.12 |
| 52-Week Low | 1.04 |
| Volume | 8.31M |
| Average Volume | 7.84M |
| Market Cap | 836.25M |
| PE | -10.92 |
| EPS | -0.12 |
| Moving Average 50 Days | 1.25 |
| Moving Average 200 Days | 1.34 |
| Change | -0.12 |
If you invested $1000 in Geron Corporation (GERN) 10 years ago, it would be worth $379.71 as of January 14, 2026 at a share price of $1.31. Whereas If you bought $1000 worth of Geron Corporation (GERN) shares 5 years ago, it would be worth $770.59 as of January 14, 2026 at a share price of $1.31.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Geron Corporation Provides 2026 Financial Guidance
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
2026 RYTELO® (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and streamlined operations to support path toward buildi
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
GlobeNewswire Inc.
Dec 11, 2025 1:00 PM GMT
Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commerci
Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS
GlobeNewswire Inc.
Dec 08, 2025 1:02 PM GMT
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independence in low